Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) doses its second patient in the phase one clinical trial of its CHECKvacc drug candidate on patients with triple negative breast cancer (TNBC)
- The study aims to evaluate the safety and efficacy of the CHECKvacc drug when administered within a tumour against metastatic TNBC
- The current trial design will involve a dose escalation, followed by an expansion of up to 12 patients at the final dose
- Imugene dropped 6.86 per cent, trading at 47.5 cents at 10:30 am AEDT
Imugene (IMU) has dosed its second patient in the phase one clinical trial of its CHECKvacc drug candidate on patients with triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer affecting about 20 per cent of all breast cancer patients, with a median survival of 12 months.
The dosing took place at the City of Hope, an independent cancer research and treatment centre near Los Angeles. The dosing follows the first patient clearing the 28-day safety window between dosages.
The purpose of the study is to evaluate the safety and efficacy of administration within a tumour of the CHECKvacc drug against metastatic TNBC.
CHECKvacc was designed to selectively kill tumour cells and activate the immune system against cancer cells. Scientifically known as CF33-hNIS-antiPDL1, the candidate is an immune checkpoint inhibitor armed chimeric vaccinia poxvirus.
The current trial design, entitled “A Phase I Study of Intratumoural Administration of CF33-hNIS-antiPDL1 in Patients with Advanced or Metastatic Triple Negative Breast Cancer” will involve a dose escalation, followed by an expansion to 12 patients at the final dose, which will be the recommended phase two dose.
“As this is our first Oncolytic Virotherapy in the clinic, it’s great to have no safety issues thus far with our first patient and we are very pleased to see our second patient joining the trial immediately following the FDA specified 28-day stagger between patient dosing,” Imugene MD & CEO Leslie Chong said.
“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with TNBC.”
Imugene dropped 6.86 per cent, trading at 47.5 cents at 10:30 am AEDT.
